Literature DB >> 22298652

Controlling the stem cell compartment and regeneration in vivo: the role of pluripotency pathways.

Kirsty Greenow1, Alan R Clarke.   

Abstract

Since the realization that embryonic stem cells are maintained in a pluripotent state through the interplay of a number of key signal transduction pathways, it is becoming increasingly clear that stemness and pluripotency are defined by the complex molecular convergence of these pathways. Perhaps this has most clearly been demonstrated by the capacity to induce pluripotency in differentiated cell types, so termed iPS cells. We are therefore building an understanding of how cells may be maintained in a pluripotent state, and how we may manipulate cells to drive them between committed and pluripotent compartments. However, it is less clear how cells normally pass in and out of the stem cell compartment under normal and diseased physiological states in vivo, and indeed, how important these pathways are in these settings. It is also clear that there is a potential "dark side" to manipulating the stem cell compartment, as deregulation of somatic stem cells is being increasingly implicated in carcinogenesis and the generation of "cancer stem cells." This review explores these relationships, with a particular focus on the role played by key molecular regulators of stemness in tissue repair, and the possibility that a better understanding of this control may open the door to novel repair strategies in vivo. The successful development of such strategies has the potential to replace or augment intervention-based strategies (cell replacement therapies), although it is clear they must be developed with a full understanding of how such approaches might also influence tumorigenesis.

Entities:  

Mesh:

Year:  2012        PMID: 22298652     DOI: 10.1152/physrev.00040.2010

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  15 in total

Review 1.  Cancer stem cells, cancer cell plasticity and radiation therapy.

Authors:  Erina Vlashi; Frank Pajonk
Journal:  Semin Cancer Biol       Date:  2014-07-12       Impact factor: 15.707

Review 2.  Krüppel-like factor 4 (KLF4): What we currently know.

Authors:  Amr M Ghaleb; Vincent W Yang
Journal:  Gene       Date:  2017-02-22       Impact factor: 3.688

Review 3.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

4.  Effects of 3D microwell culture on initial fate specification in human embryonic stem cells.

Authors:  Cheston Hsiao; Matthew Tomai; Jeremy Glynn; Sean P Palecek
Journal:  AIChE J       Date:  2014-04       Impact factor: 3.993

Review 5.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 6.  Pharmacological targets of breast cancer stem cells: a review.

Authors:  Sai Kiran S S Pindiprolu; Praveen T Krishnamurthy; Pavan Kumar Chintamaneni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-02-23       Impact factor: 3.000

Review 7.  Biotechnological approaches to the treatment of aspermatogenic men.

Authors:  Pedro Manuel Aponte; Stefan Schlatt; Luiz Renato de Franca
Journal:  Clinics (Sao Paulo)       Date:  2013       Impact factor: 2.365

Review 8.  Targeting cancer stem cells by using the nanoparticles.

Authors:  In-Sun Hong; Gyu-Beom Jang; Hwa-Yong Lee; Jeong-Seok Nam
Journal:  Int J Nanomedicine       Date:  2015-09-10

9.  Neural crest stem cells from dental tissues: a new hope for dental and neural regeneration.

Authors:  Gaskon Ibarretxe; Olatz Crende; Maitane Aurrekoetxea; Victoria García-Murga; Javier Etxaniz; Fernando Unda
Journal:  Stem Cells Int       Date:  2012-10-04       Impact factor: 5.443

10.  Regenerative strategies for craniofacial disorders.

Authors:  Catharine B Garland; Jason H Pomerantz
Journal:  Front Physiol       Date:  2012-12-14       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.